ICI Pharma's Nolvadex (tamoxifen)
Executive Summary
ICI Pharma's Nolvadex (tamoxifen): Anti-estrogen drug receives supplemental approval for use in treating breast cancer in premenopausal women, as alternative to mastectomy. The oral hormone product is already indicated as a treatment for postmenopausal breast cancer and for use either alone or in combination with other anticancer agents following surgery in postmenopausal node-positive patients. The company estimates the U.S. patient population for the new indication at 14,000: 5,000 women who have advanced disease at diagnosis and 9,000 women with recurring disease.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.